Peritoneal cancer - Pipeline Insight, 2025

DelveInsight’s, “Peritoneal cancer - Pipeline Insight, 2025” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Peritoneal cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Peritoneal cancer: Understanding

Peritoneal cancer: Overview

The invasion of the serous membrane lining the abdominal cavity, viscera, and coelom by malignant cells in amniotes is termed peritoneal surface malignancy or peritoneal cancer (PC). This cancer is categorized into primary and secondary types. Primary peritoneal cancer includes various terms like extraovarian primary peritoneal carcinoma (EOPPC) and is linked to the de novo origin of cancer in the mesothelium of the abdomen. On the other hand, secondary peritoneal cancer results from the dissemination of tumor cells in the peritoneal cavity from other sites. Treatment for peritoneal cancer often involves cytoreductive surgery (CRS) combined with intraperitoneal chemotherapy (HIPEC or EPIC), which has significantly improved patient outcomes. The latest treatments for peritoneal cancer, such as cytoreductive surgery and HIPEC, are performed at specialized centers like UT Southwestern Medical Center and have shown effectiveness in controlling symptoms and improving survival rates for select patients. Peritoneal cancer symptoms can include abdominal discomfort and pain like bloating, cramps, gas, indigestion, pressure, or swelling, frequent urination, digestive changes such as constipation, diarrhea, or nausea, loss of appetite or feeling of fullness when eating, unexplained weight loss or gain, and as the cancer progresses, symptoms like fluid buildup in the abdomen causing nausea or vomiting, stomach pain, fatigue, shortness of breath, abdominal distention, lower back pain, urinary or bowel blockage, and difficulty eating or drinking. It is crucial to seek medical attention if experiencing these symptoms as peritoneal cancer can be challenging to detect in its early stages due to its vague symptoms resembling other conditions.

Diagnosis can be done by obtaining a history regarding symptoms is frequently very helpful and this is followed by a physical exam. On physical examination, surgeon can sometimes feel tumor nodules in the abdomen or fluid (ascites). Imaging studies are helpful in evaluating patients who have symptoms suggestive of peritoneal carcinomatosis. Patients have either a CT scan or MRI of the abdomen and pelvis to confirm the presence of new or recurrent disease in the peritoneum. These imaging studies are done to assess the extent of disease in the abdomen. PET-CT can also be done to determine if disease has spread outside the abdominal cavity, such as the lungs. Laparoscopy is performed to confirm the diagnosis and determine if a patient is a candidate for cytoreductive surgery and HIPEC. Laparoscopy is a minimally invasive procedure where, through small incisions, samples of tumor (biopsies) are removed and sent to pathology to confirm a diagnosis.

Treatment options includes surgery that can be used to diagnose and treat peritoneum cancer if the place where the cancer first started to grow is unclear, or if you have a pelvic mass. This procedure is called exploratory surgery, during which the tumor is removed from the lining of the abdomen where the cancer has started to grow. Chemotherapy uses anti-cancer drugs, which are usually injected into a vein. The drugs used for peritoneum cancer are similar to those anti-cancer drugs used for treating ovarian cancer. Depending on the type of chemotherapy drugs used, this treatment can be given weekly or every two to three weeks. In most cases, patients receive the treatment on an outpatient basis. Targeted Therapy like Avastin (bevacizumab) is one targeted therapy used to treat peritoneal cancer that has come back after other treatments (recurrent). It works by blocking the growth of blood vessels that feed tumors. Another type of targeted treatment, poly (ADP-ribose) polymerase inhibitors (PARP inhibitors), is used to block the repair mechanisms that occur during cell division. This helps slow or stop tumor growth.

""Peritoneal cancer- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the peritoneal cancer pipeline landscape is provided which includes the disease overview and peritoneal cancer treatment guidelines. The assessment part of the report embraces, in depth peritoneal cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peritoneal cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence peritoneal cancer R&D. The therapies under development are focused on novel approaches to treat/improve peritoneal cancer.

Peritoneal cancer Emerging Drugs Chapters

This segment of the peritoneal cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Peritoneal cancer Emerging Drugs

• Masitinib: AB Science

Masitinib is an orally administered tyrosine kinase inhibitor. It modulates the activity of mast cells and macrophages, important cells for immunity, through targeting a limited number of kinases without inhibiting, at therapeutic doses, kinases associated with known toxicities. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. Masitinib's mechanism of action in peritoneal cancer involves inhibiting tumor growth by targeting specific kinases like KIT and PDGFR, crucial for cancer progression, without causing general toxicity. Currently, the drug is in Phase III stage of its clinical trial for the treatment of peritoneal cancer.

• Azenosertib: Zentalis Pharmaceuticals

Azenosertib is a potentially first-in-class and best-in-class small molecule Wee1 inhibitor in development for the treatment of cancer. Inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death. Currently, there are no FDA-approved WEE1 inhibitors, and we have designed Azenosertib to have advantages over other investigational therapies, including superior selectivity and pharmacokinetic properties. Currently, the drug is in Phase II stage of its clinical trial for the treatment of peritoneal cancer.

• IMGN151: ImmunoGen

IMGN151 is a next-generation ADC, designed to address the unmet needs of cancer patients with tumor types expressing lower levels of folate receptor alpha (FRα). IMGN151 comprises an asymmetric, bivalent, biparatopic antibody targeting two independent epitopes of FRα, linked to a highly potent maytansinoid derivative, DM21, via a cleavable peptide linker with enhanced stability, longer half-life, and increased bystander activity. Currently, the drug is in Phase I stage of its clinical trial for the treatment of peritoneal cancer.

Further product details are provided in the report……..

Peritoneal cancer: Therapeutic Assessment

This segment of the report provides insights about the different peritoneal cancer drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Peritoneal cancer
• There are approx. 55+ key companies which are developing the therapies for Peritoneal cancer. The companies which have their peritoneal cancer drug candidates in the most advanced stage, i.e. Phase III include, AB Science.
• Phases

DelveInsight’s report covers around 60+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Peritoneal cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peritoneal cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peritoneal cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging peritoneal cancer drugs.

Peritoneal cancer Report Insights

• Peritoneal cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Peritoneal cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Peritoneal cancer drugs?
• How many Peritoneal cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peritoneal cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Peritoneal cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Peritoneal cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Zentalis Pharmaceuticals
• Zenith Epigenetics
• Mersana Therapeutics
• Seagen
• Sutro Biopharma
• Shattuck Labs
• Clover Biopharmaceuticals
• Rhizen Pharmaceutical
• Oncoinvent
• ImmunoGen
• Arsenal Biosciences
• EMD Serono Research & Development Institute
• Medicenna Therapeutics
• Array BioPharma

Key Products

• Azenosertib
• ZEN003694
• XMT-1660
• Tisotumab vedotin
• STRO-002
• SL-172154
• SCB-313
• RP12146
• Radspherin
• IMGN151
• AB-1015
• M6620
• MDNA11
• MEK162

Please Note: It will take 5-6 business days to complete the report upon order confirmation. Show more